Visión generalGráficoNoticiasTraderScreen

UBS Knock-Out IDP/  DE000UM34XW3  /

EUWAX
13/11/2024  17:53:38 Diferencia-0.010 Bid22:00:24 Ask22:00:24 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
0.610EUR -1.61% -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 BIOGEN INC. DL -,000... 103.1634 - 31/12/2078 Call
TeleTrader 30/10 Biogen's Q3 revenue down 3% to $2.5 billion
TeleTrader 01/08 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 30/07 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 30/07 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 26/07 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 02/07 Biogen Completes Acquisition of Human Immunology Biosciences
GlobeNewswire 28/06 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 24/06 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 10/06 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 03/06 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 30/05 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 22/05 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 21/05 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 16/05 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 15/05 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 02/05 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 25/04 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 24/04 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 23/04 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 02/04 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 06/03 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 04/03 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 23/02 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 13/02 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 12/02 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...